Literature DB >> 31899798

The severe spontaneous bleeding phenotype in a novel hemophilia A rat model is rescued by platelet FVIII expression.

Qizhen Shi1,2,3,4, Jeremy G Mattson1, Scot A Fahs1, Aron M Geurts5, Hartmut Weiler1,6, Robert R Montgomery1,2,3,4.   

Abstract

Previous studies have shown that platelet-specific factor VIII (FVIII) expression (2bF8) restores hemostasis and induces immune tolerance in hemophilia A (HA) mice even with preexisting inhibitors. Here we investigated for the first time whether platelet FVIII expression can prevent severe spontaneous bleeding in rat HA, a model mimicking the frequent spontaneous bleeding in patients with severe HA. A novel FVIII-/- rat model in a Dahl inbred background (Dahl-FVIII-/-) with nearly the entire rat FVIII gene inverted was created by using a CRISPR/Cas9 strategy. There was no detectable FVIII in plasma. Spontaneous bleeding in the soft tissue, muscles, or joints occurred in 100% of FVIII-/- rats. Sixty-one percent developed anti-FVIII inhibitors after ≥2 doses of recombinant human FVIII infusion. However, when 2bF8 transgene was crossed into the FVIII-/- background, none of the resulting 2bF8tg+FVIII-/- rats (with platelet FVIII levels of 28.26 ± 7.69 mU/108 platelets and undetectable plasma FVIII) ever had spontaneous bleeding. When 2bF8tg bone marrow (BM) was transplanted into FVIII-/- rats, only 1 of 7 recipients had a bruise at the early stage of BM reconstitution, but no other spontaneous bleeding was observed during the study period. To confirm that the bleeding diathesis in FVIII-/- rats was ameliorated after platelet FVIII expression, rotational thromboelastometry and whole-blood thrombin generation assay were performed. All parameters in 2bF8tg BM transplantation recipients were significantly improved compared with FVIII-/- control rats. Of note, neither detectable levels of plasma FVIII nor anti-FVIII inhibitors were detected in 2bF8tg BM transplantation recipients. Thus, platelet-specific FVIII expression can efficiently prevent severe spontaneous bleeding in FVIII-/- rats with no anti-FVIII antibody development.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31899798      PMCID: PMC6960468          DOI: 10.1182/bloodadvances.2019000944

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  42 in total

1.  WAG-F8(m1Ycb) rats harboring a factor VIII gene mutation provide a new animal model for hemophilia A.

Authors:  C J Booth; M B Brooks; S Rockwell; J W Murphy; H M Rinder; D Zelterman; M J Paidas; S R Compton; P W Marks
Journal:  J Thromb Haemost       Date:  2010-11       Impact factor: 5.824

2.  Frequency of intron 1 and 22 inversions of Factor VIII gene in Mexican patients with severe hemophilia A.

Authors:  Johanna Milena Mantilla-Capacho; Claudia Patricia Beltrán-Miranda; Hilda Luna-Záizar; Lilia Aguilar-López; María Amparo Esparza-Flores; Beatriz López-Guido; Rogelio Troyo-Sanromán; Ana Rebeca Jaloma-Cruz
Journal:  Am J Hematol       Date:  2007-04       Impact factor: 10.047

3.  Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies.

Authors:  Qizhen Shi; David A Wilcox; Scot A Fahs; Hartmut Weiler; Clive W Wells; Brian C Cooley; Drashti Desai; Patricia A Morateck; Jack Gorski; Robert R Montgomery
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

4.  Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A.

Authors:  Q Shi; D A Wilcox; S A Fahs; J Fang; B D Johnson; L M DU; D Desai; R R Montgomery
Journal:  J Thromb Haemost       Date:  2007-02       Impact factor: 5.824

Review 5.  Hemophilia Gene Therapy: Ready for Prime Time?

Authors:  Thierry VandenDriessche; Marinee K Chuah
Journal:  Hum Gene Ther       Date:  2017-08-03       Impact factor: 5.695

6.  Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A.

Authors:  L Bi; A M Lawler; S E Antonarakis; K A High; J D Gearhart; H H Kazazian
Journal:  Nat Genet       Date:  1995-05       Impact factor: 38.330

Review 7.  Review of immune tolerance induction in hemophilia A.

Authors:  S J Schep; R E G Schutgens; K Fischer; M L Boes
Journal:  Blood Rev       Date:  2018-02-15       Impact factor: 8.250

Review 8.  The epidemiology of inhibitors in haemophilia A: a systematic review.

Authors:  J Wight; S Paisley
Journal:  Haemophilia       Date:  2003-07       Impact factor: 4.287

9.  Comparison of platelet-derived and plasma factor VIII efficacy using a novel native whole blood thrombin generation assay.

Authors:  C K Baumgartner; G Zhang; E L Kuether; H Weiler; Q Shi; R R Montgomery
Journal:  J Thromb Haemost       Date:  2015-11-25       Impact factor: 5.824

Review 10.  Platelet-Targeted Gene Therapy for Hemophilia.

Authors:  Qizhen Shi
Journal:  Mol Ther Methods Clin Dev       Date:  2018-02-07       Impact factor: 6.698

View more
  4 in total

Review 1.  Rat models of human diseases and related phenotypes: a systematic inventory of the causative genes.

Authors:  Claude Szpirer
Journal:  J Biomed Sci       Date:  2020-08-02       Impact factor: 8.410

Review 2.  Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A.

Authors:  Yuanhua Cai; Qizhen Shi
Journal:  Front Immunol       Date:  2020-06-12       Impact factor: 7.561

Review 3.  Recent Advances in the Production of Genome-Edited Rats.

Authors:  Masahiro Sato; Shingo Nakamura; Emi Inada; Shuji Takabayashi
Journal:  Int J Mol Sci       Date:  2022-02-25       Impact factor: 5.923

4.  Thromboelastometry assessment of hemostatic properties in various murine models with coagulopathy and the effect of factor VIII therapeutics.

Authors:  Jocelyn A Schroeder; Erin A Kuether; Juan Fang; Weiqing Jing; Hartmut Weiler; David A Wilcox; Robert R Montgomery; Qizhen Shi
Journal:  J Thromb Haemost       Date:  2021-07-23       Impact factor: 16.036

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.